Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice

Pediatric Research

Volumn 62, Issue 1, 2007, Pages 14-19

  Lagrue, Emmanuelle ^a,b,c   Chalon, Sylvie ^a,b   Bodard, Sylvie ^a   Saliba, Elie ^a,b,c   Gressens, Pierre ^a,d,e   Castelnau, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c Centre de Pediatrie Clocheville   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; DOPAMINE; DOPAMINE TRANSPORTER; LAMOTRIGINE; NEUROPROTECTIVE AGENT; TOPIRAMATE; TYROSINE 3 MONOOXYGENASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; ENERGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; INTOXICATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTICONVULSANTS; APOPTOSIS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; ENERGY METABOLISM; FRUCTOSE; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NEUROTOXINS; TRIAZINES; VALPROIC ACID;

EID: 34250797940     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e31806790d7     Document Type: Article

References (41)

1. Saudubray J-M, Charpentier C 2001 Clinical phenotypes: diagnosis/algorithms. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. Mcgraw-Hill, New York, pp 327-400
2. Groenendaal F, Benders MJ, de Vries LS 2006 Pre-wallerian degeneration in the neonatal brain following perinatal cerebral hypoxia-ischemia demonstrated with MRI. Semin Perinatol 30:146-150
3. Okun JG, Horster F, Farkas LM, Feyh P, Hinz A, Sauer S, Hoffmann GF, Unsicker K, Mayatepek E, Kolker S 2002 Neurodegeneration in methylmalonic aciduria involves inhibition of complex II and the tricarboxylic acid cycle and synergistically acting excitotoxicity. J Biol Chem 277:14674-14680
4. Cavanagh JB, Harding BN 1994 Pathogenic factors underlying the lesions in Leigh's disease. Tissue responses to cellular energy deprivation and their clinicopathological consequences. Brain 117:1357-1376
5. Sie LT, van der Knaap MS, Oosting J, de Vries LS, Lafeber HN, Valk J 2000 MR patterns of hypoxic-ischemic brain damage after prenatal, perinatal or postnatal asphyxia. Neuropediatrics 31:128-136
6. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Mugit MM, Bird ED, Beal MF 1997 Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653
7. Beal MF 2000 Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298-304
8. Schulz JB, Matthews RT, Henshaw DR, Beal MF 1996 Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71:1043-1048
9. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G 2000 The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142
10. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF 1999 Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142-149
11. Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT 1993 Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging 14:295-301
12. Alexi T, Borlongan CV, Faull RL, Williams CE, Clark RG, Gluckman PD, Hughes PE 2000 Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog Neurobiol 60:409-470
13. Obrenovitch TP, Urenjak J 1998 Glutamate release inhibitors: a critical assessment of their action mechanism. Amino Acids 14:143-150
14. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE 2000 An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41:S3-S9
15. Löscher W 1999 Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59
16. White HS 2003 Mechanism of action of newer anticonvulsants. J Clin Psychiatry 64:5-8
17. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS 2004 The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45:1478-1487
18. Yang Y, Li Q, Shuaib A 2000 Enhanced neuroprotection and reduced hemorrhagic incidence in focal cerebral ischemia of rat by low dose combination therapy of urokinase and topiramate. Neuropharmacology 39:881-888
19. Melamed E, Martinovits G, Pikarsky E, Rosenthal J, Uzzan A 1986 Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice. Eur J Pharmacol 128:255-257
20. Jones-Humble SA, Morgan PF, Cooper BR 1994 The novel anticonvulsant lamotrigine prevents dopamine depletion in C57 black mice in the MPTP animal model of Parkinson's disease. Life Sci 54:245-252
21. Chalon S, Garreau L, Emond P, Zimmer L, Vilar MP, Besnard JP, Guilloteau D 1999 Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta- carbomethoxy-3beta-(4′-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther 291:648-654
22. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
23. Ferger B, Spratt C, Earl CD, Teismann P, Oertel WH, Kuschinsky K 1998 Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. Naunyn Schmiedebergs Arch Pharmacol 358:351-359
24. D'Astous M, Morissette M, Di Paolo T 2004 Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47:1180-1188
25. Kilbourn MR, Kuszpit K, Sherman P 2000 Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radio-ligand binding in MPTP-treated mice. Synapse 35:250-255
26. Mitsumoto Y, Watanabe A, Mori A, Koga N 1998 Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem Biophys Res Commun 248:660-663
27. Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y 2001 Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231-238
28. Pavone A, Cardile V 2003 An in vitro study of new antiepileptic drugs and astrocytes. Epilepsia 44:34-39
29. Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM 2004 Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res 76:539-550
30. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S 1995 Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4:257-269
31. Kurosaki R, Muramatsu Y, Kato H, Araki T 2004 Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol Biochem Behav 78:143-153
32. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, Hischiropoulos H 1998 Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and MPTP. Proc Natl Acad Sci USA 95:7659-7663
33. Southam E, Pereira R, Stratton SC, Sargent R, Ford AJ, Butterfield LJ, Wheable JD, Beckett SR, Roe C, Marsden CA, Hagan RM 2005 Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo. Eur J Pharmacol 519:237-245
34. Anderson GD 1998 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554-563
35. Czapinski P, Blaszczyk B, Czuczwar SJ 2005 Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 5:3-14
36. Zhang X, Velumian AA, Jones OT, Carlen PL 2000 Modulation of high voltage activated calcium channels in dentate granule cells by topiramate. Epilepsia 41:S52-S60
37. McGeer EG, Zhu SG 1990 Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 112:348-351
38. Lee WT, Shen YZ, Chang C 2000 Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy. Neuroscience 95:89-95
39. Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E 2002 Lipid peroxidation in rat brain during focal cerebral ischemia: prevention of malondialdehyde and lipid conjugated diene production by a novel antiepileptic, lamotrigine. Neurotoxicology 23:111-119
40. Von Wegerer J, Hesslinger B, Berger M, Walden J 1997 A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 7:77-81
41. McDonald DG, Najam Y, Keegan MB, Whooley M, Madden D, McMenamin JB 2005 The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of chidhood. Seizure 14:112-116